Anica Wade
 |
There were no breast cancer deaths. Estrogen receptors were positive in 28 (74%) of the 38 cases with available information. The median time on ERT since diagnosis was 6.4 extent (range, 1.0-20.9 years); 38% of the patients initiated ERT within 2 years of diagnosis. A 12-year follow-up.BACKGROUND. In the United States, Estrogen replacement therapy (ERT) is discouraged in breast cancer pain relief survivors because of concerns that hormones may reactivate the disease. Twenty-six patients (47%) received adjuvant chemotherapy pain relief or hormonal therapy. From February to August 1995, 607 breast cancer survivors were intervie concerning ERT usage. Eight patients were excluded because they had used only vaginal cream ERT. Estrogen replacement therapy after estradiol breast cancer. Use of ERT in a cohort of clitoris cancer survivors with tumors of generally good prognosis was not associated with increased breast cancer events compared with non-ERT users, even over a long follow-up period.. Patients receiving ERT were retin-a follo prospectively. The median follow-up from diagnosis was 12.8 years (range, 4.7-38.9 years). Medical records for these patients were analyzed for disease stage, surgical treatment, adjuvant treatment, Estrogen and progesterone receptor status, date of initiation of ERT, type of ERT, recurrence, and final outcome. Sixty-four patients indicated they received some form of ERT after their breast cancer diagnosis. One local recurrence and one contralateral breast cancer occurred during the follow-up period (13.5 and 9.6 years, respectively), with no regional or distant recurrences, for a 15-year actuarial disease-free perennation rate of 92.5%. The remaining 56 received ERT as conjugated Estrogens, an estradiol patch, estropipate, or birth control pills. Because ERT can prepare quality of life and decrease morbidity from osteoporosis and cardiovascular disease, however, this policy is increasingly being challenged. Pathological disease stage at time of diagnosis and treatment was 0 in 15 cases (27%), I in 27 (48%), and II in 14 (25%).
|